Average of confirmed sales; the main valuation baseline.
Lowest active listing; an asking price, not a completed sale.
Reference-price movement; low volume can make it unstable.
More sales reduce the impact of individual transactions.
Sales answer “what is it worth”; listings answer “what does an available copy cost”.
Seller asking prices. They show availability but do not prove demand.
| DATE | SOURCE | Price | Change |
|---|---|---|---|
| 2026-10-10 | List | €42.49 | — |
| 2026-09-12 | List | €42.49 | — |
| 2026-09-11 | List | €42.49 | — |
| 2026-09-10 | List | €42.49 | — |
| 2026-09-09 | List | €42.49 | — |
| 2026-09-08 | List | €42.49 | — |
| 2026-09-07 | List | €42.49 | — |
| 2026-09-06 | List | €42.49 | — |
| 2026-09-05 | List | €42.49 | — |
| 2026-09-04 | List | €42.49 | — |
| 2026-09-03 | List | €42.49 | — |
| 2026-09-02 | List | €42.49 | — |
| 2026-09-01 | List | €42.49 | — |
| 2026-05-11 | List | €42.49 | — |
Facing a New Trial / #054
Spain: lowest · France: above average · EU average €41.16Choose a region above to inspect its prices and history.
DETAILED PRICES · Price History
| Condition/Grade | Price | LOW | HIGH | 7D CHG | Volume | Spark |
|---|---|---|---|---|---|---|
NMRAW | €38.00 | €38.00 | €44.99 | -15.6% | >5 |
Explore Lycanroc GX (sm2+ 054) Facing a New Trial JP #054, Normal from Facing a New Trial, with 76 price records for the EU market. Prices above are labeled by source, currency and condition. Asking prices and recorded sales are different measures, not interchangeable valuations.